ArticleOrthopedic research and reviews2026
Temporal Trends and Projected Burden of Bone and Articular Cartilage Malignancies in East Asia: A Systematic Analysis for the Global Burden of Disease Study 2023.
Article in Orthopedic research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant neoplasm of bone and articular cartilage (MNBAC) is a rare malignancy associated with substantial premature mortality and disability, particularly among younger populations. Comprehensive, region‑specific assessments in East Asia remain limited despite evolving demographic and epidemiologic patterns. Therefore, this study provides the first East Asia-specific epidemiological assessment of MNBAC with future projections. Methods: Utilizing estimates from the Global Burden of Disease (GBD) 2023 study, we quantified incidence, prevalence, deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) attributable to MNBAC in five East Asian countries and territories from 1990 to 2023, with projections extending to 2050 under multiple foresight scenarios. Data are presented as absolute counts and age-standardized rates with 95% uncertainty intervals. Results: Between 1990 and 2023, in East Asia, the number of incident cases increased from 9,054 to 29,877. DALYs rose from 256,249 to 615,434. Over the same period, age-standardized incidence rates per 100,000 population increased modestly, death rates declined from 3.60 to 3.09, and DALY rates decreased from 138.61 to 112.04. Projections indicate that continued increases in absolute deaths (38,467 by 2050 under the reference scenario) and DALYs (804,272), with similar or higher estimates under alternative scenarios. In contrast, age‑standardized death and DALY rates are projected to remain broadly stable or decline slightly across scenarios. Conclusion: The burden of MNBAC in East Asia was increasing, with projections indicating a continuing upward trend through 2050. While declines in age-standardized death and DALYrates suggest improved health outcomes, these metrics do not necessarily reflect substantive changes in healthcare systems. Overall, advancements in population health are unlikely to fully counterbalance the rising MNBAC burden. Targeted treatment strategies focusing on MNBAC, as well as enhancements to registries and data collection, are essential for mitigating future health losses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.